David Steinberg Recent News
Jefferies Cuts Valeant Target, But Still Sees $172 Upside
Who's The Next Big Pharma Acquisition?
Jefferies Downgrades Salix Pharmaceuticals As Raised Bid By Valeant Appears Final
Barclays Raises Valeant Pharmaceuticals' Price Target
Jefferies Sees Acquisition Of Salix Pharmaceuticals As Being Even More Likely Now
UPDATE: Jefferies Initiates Coverage On Amphastar Pharmaceuticals
Getting The U.S. Economy In Order with David Steinberg and Robert Kaplan
Auxilium's Xiaflex Launch Slow, But Significant Opportunity Remains (AUXL)